Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation
end-products, and blood pressure in diabetic nephropathy.
Author(s): Noori N(1), Tabibi H(2), Hosseinpanah F(3), Hedayati M(3), Nafar M(4).
Affiliation(s): Author information:
(1)Urology and Nephrology Research Center, Shahid Beheshti University of Medical
Sciences, Tehran, Iran.
(2)Department of Clinical Nutrition & Dietetics, Faculty of Nutrition Sciences and
Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
(3)Prevention & Treatment of Obesity Research Center, Research Institute for
Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
(4)Department of Nephrology, Shahid Labbafi Nejad Hospital, Shahid Beheshti
University of Medical Sciences, Tehran, Iran.
Publication date & source: 2013, Int J Vitam Nutr Res. , 83(2):77-85
This study was designed to investigate the effects of combined administration of
lipoic acid and pyridoxine on albuminuria, oxidative stress, blood pressure,
serum advanced glycation end-products, nitric oxide (NO), and endothelin-1 in
patients with diabetic nephropathy. Thirty-four patients were randomly assigned
to either a supplement group or a placebo group. The patients in the supplement
group received 800 mg lipoic acid and 80 mg pyridoxine daily for 12 weeks,
whereas the placebo group received corresponding placebos. Urinary albumin, serum
malondialdehyde (MDA), and systolic blood pressure decreased significantly in the
supplement group compared to the placebo group (p < 0.05). Serum NO increased in
the supplement group compared to the placebo group (p < 0.05). Serum pentosidine
and carboxymethyl lysine decreased significantly in the supplement group at the
end of week 12 compared to baseline (p < 0.05). No statistically significant
differences were observed between the two groups in mean changes of serum
endothelin-1, glucose, and diastolic blood pressure. The present study indicates
that combined administration of lipoic acid and pyridoxine improves albuminuria
in patients with diabetic nephropathy by reducing oxidative stress, advanced
glycation end-products, and systolic blood pressure. The reduction in
microalbuminuria may be of benefit in retarding the progression of diabetic
nephropathy.
|